Unnecessary Expense - by Charles Theuer & Bonne Adams & Mark Wiggins & Scott Brown (Hardcover)

Book Synopsis

The drug development process in the United States has become so weighted down by a business-as-usual paradigm that an average of more than $2 billion is spent to secure FDA approval for every new drug. Because the investment required is so extreme, drug development companies are understandably focused on discovering and developing drugs designed for large patient populations: diseases experienced by millions, such as high blood pressure, diabetes, or some of the more common cancers.
In Unnecessary Expense, Dr. Charles Theuer, CEO of TRACON Pharmaceuticals, outlines the problem and offers a solution: an aligned and streamlined model that emphasizes quality and reduces the time and cost of drug development, while also harnessing global innovation to benefit patients with rare diseases in urgent need of new treatments. Here Dr. Theuer shows the value of a pharmaceutical paradigm shift, to enable the development of drugs for patients who need them, at a fraction of the time and cost.

Review Quotes

"High quality drug candidates are increasingly being discovered abroad that have adequate patent protection and can serve as a foundation for accelerated drug development. As foreign sources become more sophisticated and aligned with FDA preclinical requirements, this approach will only become more attractive. Dr. Theuer and his colleagues at TRACON present a cost-efficient drug development platform that solves the problem of accessing the US pharmaceutical market for foreign firms by providing a return on investment even on drugs intended for rare diseases, while simultaneously benefitting US patients." -- BILL RASTETTER, PHD Chairman, Neurocrine Biosciences, Fate Therapeutics, Daré Bioscience, and San Diego Squared; past Chairman, Biogen Idec and Illumina

"This book by Dr. Charles Theuer and his colleagues offers an innovative approach to drug development. The core of the new approach, an independent CRO model, promises to enable life science companies to develop new medicines faster, with less expense, and without sacrificing quality. The book is a must-read for anyone in the industry interested in bringing new medicines to market." --JOHN COGAN, PHD Former Lead Independent Director, Gilead Sciences, Inc.; Senior Fellow, Hoover Institution, Stanford University